Abstract：
Chronic lymphocytic leukemia (CLL) is the most common leukemia in western societies, recognized by clinical and molecular heterogeneity. Despite the success of targeted therapies, acquired resistance remains a challenge for relapsed and refractory CLL, as a consequence of mutations in the target or the upregulation of other survival pathways leading to the progression of the disease. Research on proteins that can trigger such pathways may define novel therapies for a successful outcome in CLL such as the receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is a signaling receptor for Wnt5a, with an important role during embryogenesis. The aberrant expression on CLL cells and several types of tumors, is involved in cell proliferation, survival, migration as well as drug resistance. Antibody-based immunotherapies and small-molecule compounds emerged to target ROR1 in preclinical and clinical studies. Efforts have been made to identify new prognostic markers having predictive value to refine and increase the detection and management of CLL. ROR1 can be considered as an attractive target for CLL diagnosis, prognosis, and treatment. It can be clinically effective alone and/or in combination with current approved agents. In this review, we summarize the scientific achievements in targeting ROR1 for CLL diagnosis, prognosis, and treatment.
摘要：
慢性淋巴细胞白血病（CLL）是西方社会最常见的白血病，临床和分子异质性认可。尽管靶向治疗取得了成功,获得性耐药性仍然是复发性和难治性CLL的挑战，作为目标突变或其他存活途径上调导致疾病进展的结果。对可以触发此类途径的蛋白质的研究可以为CLL的成功结果定义新疗法，例如受体酪氨酸激酶样孤儿受体1（ROR1）。ROR1是Wnt5a的信号受体，在胚胎发生过程中具有重要作用。CLL细胞和几种类型肿瘤的异常表达，参与细胞增殖，生存,迁移以及耐药性。基于抗体的免疫疗法和小分子化合物在临床前和临床研究中出现靶向ROR1。已经努力鉴定具有预测价值的新的预后标志物,以改进和增加CLL的检测和管理。ROR1可以被认为是CLL诊断的一个有吸引力的目标，预后,和治疗。它可以单独和/或与目前批准的药物组合在临床上有效。在这次审查中,我们总结了针对ROR1进行CLL诊断的科学成就，预后,和治疗。
